Reporter virus particles (RVPs) package the capsid-preMembrane-envelope (C-prM-E) gene construct of ZIKV (GenBank: KU321639.1, SPH2015 strain) and a Renilla luciferase reporter.

• Anti-Zika virus neutralizing antibody screening at high throughput
• Anti-Zika virus drug screening at high throughput
• Zika virus vaccine efficacy evaluation at high throughput
• Zika virus pseudovirus transduction of target cells for viral entry, receptor recognition, cellular tropism and functional studies, such as ADCC or ADE analysis

Infection of cells with this RVP carrying Renilla luciferase reporter results in high level Renilla luciferase activity. See our titration result showing that the starting 2-fold diluted RVP-infected target cells (Vero) generates signal ~100000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of two published monoclonal antibodies (mAbs) – domain Ⅲ specific ZV67 and quaternary EDE1-C8.

Size: 200 μl with recommended 1000-fold dilution. We recommend to use it at a dilution fold where the signal of RVP infection is 1000-fold higher than uninfected control (cell alone as background), although 100 to 1000-fold high is acceptable. Can be used for 2000 reactions (100 μl diluted virus) or 5000 reactions if using reduced amount of RVP (40 μl diluted virus).

Use protocol: Download complete protocols from our website. Briefly, incubate 100 μl diluted virus with 100 μl your sample in each well of 96-well plate with at least one duplicate for 30 to 60 min at 37 °C. Then add 100 μl target cells (Vero or others expressing receptor). Read Renilla luciferase signal next day. For protocol using reduced amount, incubate 40 μl diluted virus with 10 μl your sample in each well of 96-well plate for 30 to 60 min at 37 °C. Then add 25 μl target cells. Add 150 μl fresh media next day and read signal on Day 3.